True Leaf Medicine International Ltd. Announces Close of Private Placement and Debt Conversion

2016-01-18 - For Immediate Release
 
Vancouver - True Leaf Medicine International Ltd. (CSE: MJ) is pleased to announce that it has closed a private placement of 2,005,953 units at a price of $0.105 per unit, yielding gross proceeds of $210,625 to be used to facilitate a move to a larger-scale manufacturing facility in Ontario, Canada and also for general working capital. 

Each unit is comprised of 1 common share and one-half of one warrant.  Each whole warrant is exercisable to purchase 1 additional common share of the Company at an exercise price of $0.15 per share for a period of 24 months from the issuance date of such warrants.

A commission of 8% cash and 8% broker’s warrants were payable in relation to the private placement.
The Company also announces that it has effected a conversion of $15,000 of its debt into common shares of the Company at a price of $0.105 per share (the “Debt Conversion”).  The Debt Conversion resulted in the issuance of 142,857 common shares in the capital of the Company.  No commission was payable in relation to the Debt Conversion.

The common shares and the warrants comprising the units are subject to a hold period of 4 months and 1 day from their date of issuance.

About True Leaf Medicine International Ltd:
True Leaf Medicine International Ltd. is entering the $60 billion pet industry with a line of hemp-focused pet chews and supplements marketed through natural pet health and veterinary channels in Canada and the US.  The company has also filed an application under Health Canada’s Marihuana for Medicinal Purposes Regulations (MMPR) to become a Canadian licensed producer. It has passed through the preliminary and enhanced screening process of Health Canada’s review and is currently awaiting security clearance.
 
On Behalf of the Board of Directors
True Leaf Medicine International Ltd. 

Michael Harcourt
Chairman

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. FORWARD LOOKING INFORMATION This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company's Management's Discussion and Analysis under the Company's profile on www.sedar.com. While the Company may elect to, it does not undertake to update this information at any particular time.

Contact:
Kevin Bottomley
Director
True Leaf Medicine International Ltd.
M: +1 778 389 9933
kevin@trueleaf.com
Older Post
Newer Post
Close (esc)

Site Maintenance in Progress

This website is currently undergoing maintenance. During this short period, some items may not appear as desired. We appreciate your patience and will be back in action shortly.

Age verification

By clicking enter you are verifying that you are old enough to consume alcohol.

Search

Shopping Cart

Your cart is currently empty.
Shop now